NCT00446303终止2 期
A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 39
- 试验地点
- 50
- 主要终点
- Reponse duration and cumulative incidence of relapses
研究概览
简要总结
A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission (CR or PR) after intensive chemoterapy.
The primary objective is response duration (MDS or AML)
详细描述
A academic multicentre study whose aims are to study the benefits of a maintenance therapy with 24 monthly courses af azacytidine in high-risk MDS patients, previously treated with intensive chemotherapy with obtention of a partial or complete response and not eligible for allogeneic transplantation
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •MDS with int 2 or high IPSS score eitherRAEB 1 or 2 according to the WHO classification (see appendix 1) or CMML with WBC < 13 109/l RAEB-T according to the FAB classification (see appendix 1) without t(8 ;21), inv 16 or t(16;16) AML secondary to MDS (sAML) with a confirmed MDS phase of at least 2 months with available bone marrow cytogenetics at diagnosis of AML
- •in CR or PR according to IWG criteria (see appendix 3) after one or two courses of predefined intensive chemotherapy (see page 12) with available cytogenetics at evaluation of response Aged 18 years of age or more Written Informed consent Adequate Contraception, if relevant Negative pregnancy test if relevant. Patients not eligible for the azacitidine confirmatory trial (azacitidine " versus " conventional treatment ") or unwilling to participate to it
排除标准
- •AML secondary to myeloproliferative or MDS/MPD WHO subgroups except CMML with WBC< 13 109/l
- •Therapy related MDS (after chemo or radiotherapy for a previous neoplasm or immune disorder)
- •Patients eligible for allogeneic bone marrow transplantation (with a identified donor)
- •Liver and/or kidney failures prohibiting the use of azacitidine. Creatininemia > 1.5 normal value ALAT and ASAT > 3N
- •Bilirubin > 2 N, unless due to dyserythropoiesis
- •Known hypersensitivity to azacitidine or mannitol
- •Other tumor, unstable for the last three years, except in situ uterine carcinoma or basal skin tumor
- •Uncontrolled infection,
- •WHO Performance status > 2
- •Life expectancy less than 3 months
结局指标
主要结局
Reponse duration and cumulative incidence of relapses
时间窗: 1-24 months
次要结局
- Toxicity according to WHO(1-24 months)
- Overall survival
研究者
研究点 (50)
Loading locations...
相似试验
已完成
2 期
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT01700673Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins25
已完成
2 期
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT01048034Nordic MDS Group30
已完成
2 期
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory DisordersMDSSystemic Autoimmune DiseasesNCT02985190Groupe Francophone des Myelodysplasies30
已完成
2 期
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)Acute Myelocytic LeukemiaMyelodysplastic SyndromeNCT01462578Technische Universität Dresden93
招募中
2 期
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML ProfilingAcute Myeloid LeukemiaNCT05431257Rigshospitalet, Denmark117